Moreover, drugs targeting complement activation at the C5a–C5aR1 stage in the complement pathway and drugs targeting GCS have shown marked reduction in the replication of SARS-CoV-2, as well as the SARS-CoV-2-mediated induction of innate and adaptive immune inflammation that leads to the tissue destruction and death in patients with COVID-19 [78,80,81,82,236]. This evidence concerns the gene UGCG and COVID-19.